Clinical Trials
Several clinical trials incorporate saccharin into phase-not-applicable diagnostic protocols to evaluate gustatory and mucociliary clearance pathways in physiological and respiratory conditions. These investigations—sponsored by institutional and corporate entities such as St. Paul's Hospital Canada, RAI Services Company, and Philip Morris Products S.A.—focus on chronic rhinosinusitis, smoking cessation biomarkers, and mucociliary function in smokers versus non-smokers. Recruitment statuses for these trials range from completed to unknown.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT04278950 | Unknown status | Chronic Rhinosinusitis (Diagnosis) |
St. Paul''s Hospital Canada |
2020-02-10 | Not Applicable |
| NCT04979013 | Completed | Smoking|Smoking Cessation|Tobacco Use |
RAI Services Company |
2019-05-30 | Not Applicable |
| NCT03086707 | Completed | Smokers|Never Smokers |
Philip Morris Products S.A. |
2017-01-21 | Not Applicable |
(data from https://clinicaltrials.gov, updated on 2024-05-22)
Compliance for Clinical Use
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).